Stephanie Samples O'Malley PhD

Professor of Psychiatry; Director, Division of Substance Abuse Research in Psychiatry; Deputy Chair, Clinical Research

Research Interests

Medications development for alcoholism and smoking; Risk reduction and young adult drinking; tobacco regulatory science; treatment methodology; patient treatment matching; biomarkers of treatment response

Current Projects

Yale Tobacco Center for Regulatory Science

Clinical trials of varenicline for the treatment of alcohol dependence among smokers and of naltrexone for young adult heavy drinkers

Laboratory studies to evaluate medications for substance use disorders

Validation of biomarkers for monitoring drinking in clinical trials

Secondary analyses to identify moderators and predictors of response to treatments for alcohol dependence using tree based and trajectory analyses

Training of clinician and transdisciplinary scientists


Research Summary

The goal of our laboratory is to develop more efficacious treatments for alcohol use disorders and nicotine dependence and to provide the science base for the regulation of tobacco products. Toward this end, we are conducting clinical trials to determine efficacy of medications and behavioral interventions, and laboratory studies to determine the mechanisms underlying the effects of treatment and the underlying nature of the disorder. Research on how flavors, such as methol and sweeteners, influence the use of tobacco products is underway to inform the regulation of tobacco products by the FDA.


Selected Publications

  • Rojewski AM, Toll BA, O'Malley SS. (2013). Menthol Cigarette Use Predicts Treatment Outcomes of Weight-Concerned Smokers. Nicotine Tob Res. 2013 Oct 10. [Epub ahead of print] PubMed PMID: 24113927.
  • DeMartini KS, Palmer RS, Leeman RF, Corbin WR, Toll BA, Fucito LM, O'Malley SS. (2012). Drinking Less and Drinking Smarter: Direct and Indirect Protective Strategies in Young Adults. Psychol Addict Behav. 2012 Oct 22. [Epub ahead of print] PMID: 23088406
  • Fucito LM, Park A, Gulliver SB, Mattson ME, Gueorguieva RV, O'Malley SS. (2012). Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biological Psychiatry, 72(10):832-8.PMID: 23088406
  • Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS. (2011) A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl). 2011 Jun;215(4):655-63. PMID: 21221531
  • O’Malley, S.S., Krishnan-Sarin, S., McKee, S.A., Leeman, R.F., Cooney, N.L., Meandzija, B., Wu, R., Makuch, R.W. (2009). Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trail of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology, 12(5): 589-597. PMID: 18796184
  • Anton, R.F., O’Malley, S.S., Ciraulo, D.A., et al., for the COMBINE Study Research Group (2006). Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A Randomized Controlled Trial. Journal of the American Medical Association. 295:2003-2017. PMID: 16670409
  • O’Malley, S.S., Krishnan-Sarin, S., Farren, C., Sinha, R., Kreek, M.J. (2002). Naltrexone decreases craving and alcohol self-administration in alcohol dependent subjects and activates the hypothalamo-pituitary-adrenocorticol axis. Psychopharmacology, 160:19-29 PMID: 11862370

Edit Profile